Shares of Chemours (CC) tumbled 5.87% on Tuesday following the release of the company's first-quarter 2025 earnings report, which presented a mixed picture of its financial performance and included several disappointing announcements for investors.

The chemical company reported adjusted earnings per share (EPS) of $0.13, significantly below the analyst consensus estimate of $0.21. This represents a 59.38% decrease compared to the same period last year. Despite the earnings miss, Chemours managed to outperform on the top line, reporting Q1 sales of $1.4 billion, surpassing the analyst estimate of $1.352 billion. However, the company's adjusted EBITDA of $166 million fell short of the expected $171.3 million.

Adding to investor concerns, Chemours lowered the top end of its full-year adjusted EBITDA guidance to between $825 million and $950 million, down from the previous range of $825 million to $975 million. The company also announced a drastic 65% reduction in its quarterly dividend to $0.0875 per share, citing the need to better align its capital allocation and achieve balance sheet flexibility. These factors, combined with the earnings miss, appear to be the primary drivers behind the stock's sharp decline.